About Biocon Biocon's Products & Services Research & Development Biocon's Technology Investors Media Careers CSR
 
  About Us
  Research & Development
  Biopharmaceuticals
  Branded Formulations
  Financial Results
  - Earnings call transcript Q1FY17
  - Investor Presentation
  - Chairman's AGM 2016 Speech
  - Annual Reports
  Facilities Virtual Tour
  Downloads
  - Biocon Profile
  - CMD Profile
  - Video Gallery

 Annual Report 2016

 

 Biocon Malaysia

 Biocon Academy

Email:
admissions@bioconacademy.com

 

     
 

At Biocon, we are driven by our passion to develop research-driven, cutting-edge biopharmaceuticals to address the relatively unmet needs of patients suffering from chronic diseases such as cancer, diabetes and autoimmune conditions.

Our commitment to impact global health has led us to build differentiated capabilities in the areas of biologics and complex small molecules. We have used advanced technology platforms to develop and deliver a rich portfolio of generic small molecule APIs and formulations, novel biologics and biosimilars including monoclonal antibodies, rh-Insulin and analogs.

We believe our value proposition built around differentiation and scale has enabled us to seek global leadership to provide access to affordable biopharmaceuticals for patients and partners across the globe. We are constantly engaged in pursuit of excellence to develop high quality, safe and efficacious products that can heal the world.

read more...


 
   
   
   
 

 

 

Q1FY17 Highlights
Stock Update
 
 
 
 
 
 

  Latest Press Release
 

 Sept. 19, 2016:
 Biocon appoints Suresh  Subramanian as Head of  Branded Formulations  (India) Business 

 Sept. 01, 2016:

 Kiran Mazumdar Shaw  Appointed 'Knight of the  Legion of Honour' by the  Government of France 

 Aug. 25, 2016:

 Mylan and Biocon Announce  Regulatory Submission for  Proposed Biosimilar  Trastuzumab Accepted for  Review by European  Medicines Agency

  Media Coverage
 

September, 2016:
Top French Honour for Biocon's Kiran Shaw


August, 2016:
'We have enhanced patient access to insulin across India' - Kiran Mazumdar Shaw


July, 2016:
'We need meritocracy, not mediocrity' - Kiran Mazumdar Shaw

Contact

Contact


Contact

Contact

     
  Biocon

Businesses

Recommended sites Biocon on  
  Home
About Us

Investor Relations
Media Relations
Careers
Site Map
Contact Us
Our Growth Accelerators
Fact Sheet
Branded Formulations
Biopharmaceuticals
Research Services
Active Discovery Program

ABLE
Karnataka Vision Group on BT
Syngene International
Biocon Academy

    Linked In   
       
  Report adverse event/side effects and product complaints    
       
  * Disclaimer            © 2016, Biocon. All Rights Reserved